Form 4: Zimmer Biomet Director Michelson Reports Changes in Beneficial Ownership

Director Michael Michelson reports acquisition of phantom stock units and restricted stock units under Zimmer Biomet's deferred compensation plan.

Summary

• Michael Michelson, a director of Zimmer Biomet Holdings, Inc., filed a Form 4 detailing changes in his beneficial ownership.
• The report indicates the acquisition of phantom stock units and restricted stock units under the company's deferred compensation plan.
• The phantom stock units were accrued under the Zimmer Biomet Holdings, Inc. Deferred Compensation Plan for Non-Employee Directors.
• The restricted stock units are immediately 100% vested and will be subject to mandatory deferral until the later of (1) the reporting person's termination of service as a Director or (2) the date that is three years after the grant date.
• As of May 10, 2024, Michelson beneficially owns 12,239.749 phantom stock units and 8,549.937 restricted stock units.
• The phantom stock units will be settled in shares of Company common stock within sixty days after cessation of the reporting person's service as a Director.

Sentiment

Score: 6

Explanation: The document is a routine regulatory filing, indicating standard compensation practices. It doesn't contain information that would significantly sway investor sentiment positively or negatively.

Future Outlook

The phantom stock units will be settled in shares of Company common stock within sixty days after cessation of the reporting person's service as a Director.

Industry Context

This filing is a routine disclosure related to executive compensation and holdings, common in the healthcare and medical device industry. It provides transparency regarding the alignment of director interests with shareholder value through equity-based compensation.

Comparison to Industry Standards

• Equity compensation is a standard practice among publicly traded companies, including Zimmer Biomet's competitors such as Stryker, Johnson & Johnson (DePuy Synthes), and Medtronic.
• Deferred compensation plans for non-employee directors are also common, allowing directors to defer income and potentially benefit from future stock appreciation.
• The vesting and deferral terms of the restricted stock units are typical for director compensation packages, designed to incentivize long-term commitment and alignment with shareholder interests.

Stakeholder Impact

• The disclosure provides transparency to shareholders regarding director compensation and alignment of interests.
• The equity-based compensation structure incentivizes the director to act in ways that benefit shareholders.

Key Dates